Hyperfiltration is associated with the development of microalbuminuria in patients with sickle cell anemia
Authors: Benjamin Vazquez, Binal Shah, Xu Zhang, James P. Lash, Victor R. Gordeuk, Santosh L. Saraf
Journal: American Journal of Hematology (2014)

To the Editor: We hypothesized that glomerular hyperfiltration, observed in about half of adults with sickle cell anemia (SCA) 1, may contribute to the initial stages of glomerular injury, similar to diabetic 2 and hypertensive nephropathy 3. We estimated the glomerular filtration rate (eGFR) in 356 adult patients with SCA (Hb SS: n = 346, Hb Sβ0 n = 10) receiving routine medical care at the University of Illinois at Chicago between 2008 and 2014 using the Chronic Kidney Disease Epidemiology Collaboration formula: eGFR in mL/min/1.73 m2 = 175 × (serum creatinine)−1.154× (age)−0.203 × (0.742 if female) × (1.212 if African American). Hyperfiltration was defined as eGFR ≥130 mL/min/1.73 m2 for females and ≥140 mL/min/1.73 m2 for males, similar to previous reports in SCA 1. The prevalence of hyperfiltration decreased with age (Fig. 1A) and, in 196 patients with urine albumin measured, the prevalence of albuminuria (≥30 mg/g creatinine) increased with age (Fig. 1B), as previously shown in other studies. A. Prevalence of hyperfiltration by age. The persistence of hyperfiltration (defined as an eGFR ≥ 130 mL/min/1.73 m2 in women and ≥ 140 mL/min/1.73 m2 in men) decreases with increasing age in 356 adult patients with sickle cell anemia (SCA). B. Increasing prevalence of albuminuria ≥ 30 mg/g creatinine by age in 196 patients with SCA. C. Increasing hyperfiltration category is associated with a higher risk for progressing to microalbuminuria. Hyperfiltration was associated with an incremental risk for progressing to microalbuminuria in follow up of 45 SCA patients without CKD (age-adjusted HR 2.5, 95% CI: 1.1–6.0). D. Relationship of urine nephrin and urine albumin concentrations in 32 consecutive adult SCA patients with an eGFR > 60 mL/min/1.73 m2. Eighty-eight SCA patients did not have chronic kidney disease (CKD) at baseline evaluation as evidenced by eGFR >60 mL/min/1.73 m2 and urine albumin <30 mg/g creatinine. To investigate the relationship of hyperfiltration to the development of albuminuria, we focused on 45 of these patients who had subsequent urine albumin measurements over 68 months. Urine albumin concentrations were measured by random, spot urine collections during a clinic visit and development of urine albumin ≥30 mg/g creatinine was confirmed by two consecutive determinations. Forty-three patients had Hb SS and two had Hb Sβ0 thalassemia. The median age was 27 years with a range of 18–59 years. Twenty-nine were female and 24 were on hydroxyurea (HU) therapy. Thirty patients had hyperfiltration, and this likely represents persistence of hyperfiltration into adulthood since most children have hyperfiltration. The median length of follow-up was 26 months (range 6–68) with a median number of three urine albumin assessments (range 2–8). Thirteen patients developed microalbuminuria (urine albumin 30–299 mg/g creatinine) with a median time to development of 21 months (range 11–57). No patient developed macroalbuminuria (urine albumin ≥300 mg/g creatinine). Rates of developing microalbuminuria were not different based on HU status or body-mass index (BMI) at baseline. The eGFR remained >90 mL/min/1.73 m2 in all subjects. Consistent with the role of hyperfiltration contributing to the early stages of CKD, we observed higher rates for developing microalbuminuria in patients with higher filtration categories (3 of 15 in patients without hyperfiltration, 6 of 23 with hyperfiltration but eGFR <160mL/min/1.73 m2, 4 of 7 with eGFR ≥160 mL/min/1.73 m2). Using Cox proportional hazard modeling, the unadjusted HR was 2.4 (95% CI: 1.1–5.3, P = 0.036) while the age-adjusted HR was 2.7 (95% CI: 1.1–5.8, P = 0.032) and the age and HU-adjusted HR was 2.6 (95% CI: 1.1–6.4, P = 0.031) (Fig. 1C). Nephrin, a major component of the slit diaphragm that maintains normal podocyte foot process architecture, is a sensitive urinary biomarker for glomerular injury and is detected before albuminuria develops in animal models 4. Kidney injury molecule-1 (KIM-1) is a transmembrane proximal tubular protein with increased expression after tubular injury 5. We used ELISA to measure urine concentrations of nephrin (Exocell, Philadelphia, PA) and KIM-1 (R&D Systems, Minneapolis, MD) in 32 adult SCA patients, six from the follow-up cohort just described and 26 additional consecutive outpatients with eGFR >60mL/min/1.73 m2, between March and May 2013. Urine nephrin concentration correlated significantly with eGFR (r = 0.36, P = 0.044) but urine KIM-1 concentration did not (r = 0.11, P = 0.6). Urine nephrin concentration also correlated strikingly with urine albumin concentration (r = 0.92, P < 0.0001) (Fig. 1D). Our findings are consistent with the possibility that a high eGFR causes damage to the glomerulus reflected by its correlation with a urine biomarker of glomerular injury but not with a urine biomarker of tubular injury and by the increased risk for developing microalbuminuria in SCA patients with hyperfiltration. Limitations to this study include that we did not directly measure the GFR, although the CKD-Epidemiology-based eGFR is reported to have good correlation with measured GFR in patients with SCA 6. Another potential limitation is that nephrin is expressed in the pancreas and may be circulating in the plasma and filtered through the glomerulus with albumin which will need to be evaluated in future studies. Furthermore, our study may have been underpowered to detect associations between hydroxyurea therapy or BMI and the development of microalbuminuria. In conclusion, a higher degree of persistent hyperfiltration in adults may be an important risk factor for the development of CKD in addition to other factors such as joint polymorphisms in MYH9 and APOL1. Future research is needed to understand mechanisms of how hyperfiltration may damage the glomerulus and to identify interventions to protect the kidney in this context. The project described was supported by the National Institutes of Health, National Center for Advancing Translational Sciences through Grant KL2TR000048 and by Grant K24-DK092290. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Benjamin Vazquez,1 Binal Shah,1 Xu Zhang,1 James P. Lash,2 Victor R. Gordeuk,1 and Santosh L. Saraf1* 1Department of Medicine, Section of Hematology-Oncology, University of Illinois at Chicago, Chicago IL 2Department of Medicine, Section of Nephrology, University of Illinois at Chicago, Chicago IL